Kymera Therapeutics (KYMR) Cash & Equivalents (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Cash & Equivalents for 8 consecutive years, with $144.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 60.16% year-over-year to $144.1 million; the TTM figure through Mar 2026 stood at $144.1 million (up 60.16% YoY), while the FY2025 annual figure was $357.0 million, up 196.88% from the prior year.
• Cash & Equivalents slipped to $144.1 million in Q1 2026 per KYMR's latest filing, from $357.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $357.0 million in Q4 2025 and bottomed at $33.7 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $121.2 million across 5 years, with a median of $93.5 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 47.93% — and 2025, when it jumped 396.68%.
• Kymera Therapeutics' Cash & Equivalents stood at $68.4 million in 2022, then soared by 60.78% to $110.0 million in 2023, then grew by 9.36% to $120.3 million in 2024, then jumped by 196.88% to $357.0 million in 2025, then slumped by 59.64% to $144.1 million in 2026.
• Business Quant data shows KYMR's Cash & Equivalents at $144.1 million in Q1 2026, $357.0 million in Q4 2025, and $112.9 million in Q3 2025.